Production (Stage)
Pacific Biosciences of California, Inc.
PACB
$1.14
$0.1414.00%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -5.28% | -1.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.28% | -1.86% | |||
| Cost of Revenue | -3.94% | 17.13% | |||
| Gross Profit | -10.62% | -40.33% | |||
| SG&A Expenses | -28.32% | 52.10% | |||
| Depreciation & Amortization | 5,248.72% | 0.00% | |||
| Other Operating Expenses | 307.62% | -- | |||
| Total Operating Expenses | 265.31% | 33.99% | |||
| Operating Income | -384.06% | -59.58% | |||
| Income Before Tax | -15,968.14% | 104.42% | |||
| Income Tax Expenses | -195.57% | -- | |||
| Earnings from Continuing Operations | -18,070.27% | 103.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -18,070.27% | 103.90% | |||
| EBIT | -384.06% | -59.58% | |||
| EBITDA | 23.30% | -77.22% | |||
| EPS Basic | -17,186.90% | 103.78% | |||
| Normalized Basic EPS | -360.07% | -63.85% | |||
| EPS Diluted | -17,660.98% | 103.69% | |||
| Normalized Diluted EPS | -398.96% | -51.08% | |||
| Average Basic Shares Outstanding | 4.90% | 3.69% | |||
| Average Diluted Shares Outstanding | -3.27% | 12.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||